RxDoctor Payments Data

Domenic Aiello, MD

Endocrinology, Diabetes & Metabolism · New Hartford, NYNPI 1679547111

Payments from drug & device makers

$28,495in general payments, 2019–2025

Across 49 payments — averaging $581.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$18K
  • Johnson & Johnson$10K
  • Novo Nordisk$122
  • Medtronic$115
  • Amryt Pharma Holdings Ltd$55
  • AstraZeneca$34
  • plus $40 from 2 others

What the payments were for

  • Speaking & faculty fees$25,25289%
  • Travel & lodging$2,2138%
  • Food & beverage$1,0134%
  • Education$170%

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,495 in reported general payments places this provider in the 85th percentile of 804 endocrinology, diabetes & metabolism providers in New York.

See all endocrinology, diabetes & metabolism providers in New York

Medicare billing

Part B allowed, 2024
$157,604
Medicare patients
703
Services billed
1,488

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide380$474,541
JardianceEmpagliflozin433$425,523
JanuviaSitagliptin Phosphate227$178,103
TrulicityDulaglutide116$141,565
RybelsusSemaglutide82$140,835
Tolvaptan12$121,501
FarxigaDapagliflozin Propanediol85$94,305
JanumetSitagliptin Phos/Metformin Hcl76$92,310
Humulin R U-500 KwikpenInsulin Regular, Human41$84,621
InvokanaCanagliflozin101$80,813
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog65$69,252
MounjaroTirzepatide45$64,080
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog141$62,020
Lantus SolostarInsulin Glargine,hum.Rec.Anlog337$56,256
ProliaDenosumab33$56,173

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$122$625,124500 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog$28$211,934186 claims
AstraZenecaFarxiga$34$94,30585 claims
Johnson & JohnsonInvokana$10,164$80,813101 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$17,964$55,50333 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 804 endocrinology, diabetes & metabolism providers in New York.

Other endocrinology, diabetes & metabolism in New Hartford

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →